Breast Cancer Overall Survival in France
Author(s)
Olivier Tredan, Physician1, Laura Mansi, Physician2, Yann Delpech, Physician3, Manoel Moreau, RWE expert4, Majda Le Foll-Elfounini, Project Manager5, Danko Stamenic, Statistician5, Marie Lotz, Medical advisor5, Simona Bara, Epidemiologist6.
1Centre Leon Berard, Lyon, France, 2CHRU Jean Minjoz, Besançon, France, 3Centre Antoine Lacassagne, Nice, France, 4ROCHE SAS, Boulogne-Billancourt, France, 5Roche SAS, Boulogne-Billancourt, France, 6Centre Hospitalier du Cotentin, Cherbourg-en-Cotentin, France.
1Centre Leon Berard, Lyon, France, 2CHRU Jean Minjoz, Besançon, France, 3Centre Antoine Lacassagne, Nice, France, 4ROCHE SAS, Boulogne-Billancourt, France, 5Roche SAS, Boulogne-Billancourt, France, 6Centre Hospitalier du Cotentin, Cherbourg-en-Cotentin, France.
OBJECTIVES: Overall survival (OS) at 5,10 and 12 years in French women with BC depending on cancer subtype
METHODS: Data were extracted from a 2% representative sample of the French National Claims Database. All French women aged ≥18 years old who were diagnosed with BC between 2010 and 2023 were identified using markers of BC management. HER2+ and HR+ status were determined based on the reimbursement of HER2-targeted therapy and endocrine therapy, respectively. Patients without HER2-targeted or endocrine therapy cannot be identified because of the lack of tracking drugs and were grouped into an "undefined subtype” category (e.g. Triple negative BC or HR+ with visceral crisis). OS was defined as the time from the BC diagnosis date, or otherwise from the date of the first evidence of BC specific treatment until death from any cause. OS rates were analysed using Kaplan-Meier curves of BC diagnosis or the first BC specific treatment
RESULTS: A total of 12 219 incident BC cases were identified, of which 7 878 (64,5%) were HR+ HER2- and, 1 414 HER2+ including 895 (7,3%) HER2+ RH+ and 519 (4,2%) HER2+ RH-. OS rates were 87.4% (95% CI: 85.4%, 89.2%), 80.0% (95% CI: 77.2%, 82.5%) and 72.9% (95% CI: 68.1%, 75.8%) at 5 years, 10 years and 12 years respectively in HER2+ subtype.OS rates were 88.8% (95% CI: 88.0%, 89.5%), 77.6% (95% CI: 76.3%, 78.8%) and 74.4% (95% CI: 70.5%, 77.8%) at 5 years 10 years and 12 years respectively in HR+ HER2- subtype.
CONCLUSIONS: As of today, OS rates at 12 years are similar in HER2+ and HR+ groups. However HR+ group do not include patients with visceral crisis, mainly treated with chemotherapy, overestimating our actual results for this group.
METHODS: Data were extracted from a 2% representative sample of the French National Claims Database. All French women aged ≥18 years old who were diagnosed with BC between 2010 and 2023 were identified using markers of BC management. HER2+ and HR+ status were determined based on the reimbursement of HER2-targeted therapy and endocrine therapy, respectively. Patients without HER2-targeted or endocrine therapy cannot be identified because of the lack of tracking drugs and were grouped into an "undefined subtype” category (e.g. Triple negative BC or HR+ with visceral crisis). OS was defined as the time from the BC diagnosis date, or otherwise from the date of the first evidence of BC specific treatment until death from any cause. OS rates were analysed using Kaplan-Meier curves of BC diagnosis or the first BC specific treatment
RESULTS: A total of 12 219 incident BC cases were identified, of which 7 878 (64,5%) were HR+ HER2- and, 1 414 HER2+ including 895 (7,3%) HER2+ RH+ and 519 (4,2%) HER2+ RH-. OS rates were 87.4% (95% CI: 85.4%, 89.2%), 80.0% (95% CI: 77.2%, 82.5%) and 72.9% (95% CI: 68.1%, 75.8%) at 5 years, 10 years and 12 years respectively in HER2+ subtype.OS rates were 88.8% (95% CI: 88.0%, 89.5%), 77.6% (95% CI: 76.3%, 78.8%) and 74.4% (95% CI: 70.5%, 77.8%) at 5 years 10 years and 12 years respectively in HR+ HER2- subtype.
CONCLUSIONS: As of today, OS rates at 12 years are similar in HER2+ and HR+ groups. However HR+ group do not include patients with visceral crisis, mainly treated with chemotherapy, overestimating our actual results for this group.
Conference/Value in Health Info
2025-11, ISPOR Europe 2025, Glasgow, Scotland
Value in Health, Volume 28, Issue S2
Code
CO31
Topic
Clinical Outcomes, Epidemiology & Public Health
Topic Subcategory
Relating Intermediate to Long-term Outcomes
Disease
Oncology